Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821781 | 0.93 | CYP3A4 (0.37) | CYP3A4CYP2C8 | |
| SCHEMBL18033745 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL18033743 | 0.88 | CYP3A4 (0.40) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18029185 | 0.85 | CYP3A4 (0.46) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL18033765 | 0.85 | — | — | |
| SCHEMBL17349642 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18028931 | 0.82 | CYP3A4 (0.42) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18033740 | 0.82 | CYP3A4 (0.37) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL18033787 | 0.82 | CYP3A4 (0.42) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18002671 | 0.82 | CYP3A4 (0.40) | CYP3A4CYP2C8KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2016133970-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | ZC3HAV1, TMBIM6, EIF2AK2 | CYP3A4 159/4885CYP2C8 64/4885KCNH2 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.